BioSpace News Archive

The Company’s common shares will continue to trade on the Toronto Stock Exchange (TSX) under the same symbol “CRDL” (its current symbol). Concurrent with the listing of Cardiol’s common shares on NASDAQ, the shares will cease to be quoted on the OTCQX.

Fluidigm Corporation today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations Summit Wednesday, August 11, 2021 Laguna Beach, California Panel presentation at 8:00 p.m. ET, 5:00 p.m. PT

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended June 30, 2021, and highlighted recent accomplishments.

FibroGen, Inc. reported financial results for the second quarter 2021 and provided an update on the Company’s recent developments.

Atrion Corporation announced that for the second quarter ended June 30, 2021, revenues totaled $42.7 million compared with $38.0 million for the same period in 2020.

Vor Biopharma, a cell and genome engineering company, reported financial results for the three-month period ended June 30, 2021, and provided a business update.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale University’s Department of Immunobiology.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the second quarter ended June 30, 2021.

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported its financial results for the second quarter of 2021.

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, reported financial results for the second quarter ended June 30, 2021 and provided a business update.